European Union Health Commission
Posted in EU Info on 10/06/2010 11:23 pm by admin
Usa Drugstore | Acomplia Review
Acomplia (also known as SR141716, Rimonabant, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, and Zimulti) is an anorectic anti-obesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
Acomplia is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients with a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2008, the drug was available in 56 countries.
The EU’s approval was not a blanket approval, nor did it approve Acomplia for non-obesity related problems such as smoking cessation, although off-label use of the drug is still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia.
On 21 June 2006, the European Commission approved the sale of Acomplia in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will be sold is the United Kingdom. Sales began in July 2006. Sanofi also announced that it projects that the drug will be sold shortly thereafter in Denmark, Ireland, Germany, Finland and Norway. It is expected in Belgium[3] and Sweden in 2007. Ordinary obesity will, according to official medical recommendations, not be enough to acquire the prescription in Sweden; there are additional requirements concerning abnormal blood lipid levels.
About the Author
US DRUGSTORE | Purchase any medication at discounted prices. 100% Legal.
Brussels Wants Health Warnings on iPods, MP3 Players
|
|
European Commission proposes stricter health claim regulations.(Europe): An article from: Nutraceuticals World $5.95 This digital document is an article from Nutraceuticals World, published by Rodman Publications, Inc. on September 1, 2003. The length of the article is 666 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation Detail… |
|
|
Com (93) 224 (Final) Brussels, 24 May 1993: Communication from the Commission on Collaboration between the Commission of the European Communities and the World Health Organization … |
|
|
The Contribution of Health to the Economy in the European Union: The Contribution of Human Capital to Economic Growth $63.00 In March 2000, the European Union?s Heads of State or Government came together to agree the ambitious goal of making the European Union ?the most competitive and dynamic knowledgebased economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion?. They highlighted the need to: create a knowledge-based economy and society, accelerating the proce… |